AU2020419181A1 - Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases - Google Patents

Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases Download PDF

Info

Publication number
AU2020419181A1
AU2020419181A1 AU2020419181A AU2020419181A AU2020419181A1 AU 2020419181 A1 AU2020419181 A1 AU 2020419181A1 AU 2020419181 A AU2020419181 A AU 2020419181A AU 2020419181 A AU2020419181 A AU 2020419181A AU 2020419181 A1 AU2020419181 A1 AU 2020419181A1
Authority
AU
Australia
Prior art keywords
disorder
dextromethadone
nmdar
composition
glutamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020419181A
Other languages
English (en)
Inventor
Andrea Cavalli
Sara DE MARTIN
Charles E. Inturrisi
Paolo L. Manfredi
Andrea Mattarei
Jacopo SGRIGNANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Universita degli Studi di Padova
Original Assignee
Inst Res Biomedicine
Institute for Research in Biomedicine IRB
Of Padova, University of
Universita degli Studi di Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine, Institute for Research in Biomedicine IRB, Of Padova, University of, Universita degli Studi di Padova filed Critical Inst Res Biomedicine
Publication of AU2020419181A1 publication Critical patent/AU2020419181A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
AU2020419181A 2020-01-03 2020-12-30 Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases Pending AU2020419181A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062956839P 2020-01-03 2020-01-03
US62/956,839 2020-01-03
US202062963874P 2020-01-21 2020-01-21
US62/963,874 2020-01-21
US202062993188P 2020-03-23 2020-03-23
US62/993,188 2020-03-23
US202063010391P 2020-04-15 2020-04-15
US63/010,391 2020-04-15
US202063031785P 2020-05-29 2020-05-29
US63/031,785 2020-05-29
PCT/US2020/067498 WO2021138443A1 (en) 2020-01-03 2020-12-30 Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases

Publications (1)

Publication Number Publication Date
AU2020419181A1 true AU2020419181A1 (en) 2022-07-21

Family

ID=76687448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020419181A Pending AU2020419181A1 (en) 2020-01-03 2020-12-30 Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases

Country Status (12)

Country Link
US (1) US20230017786A1 (https=)
EP (1) EP4085044A4 (https=)
JP (2) JP2023509484A (https=)
KR (1) KR20220164470A (https=)
CN (1) CN115397804A (https=)
AU (1) AU2020419181A1 (https=)
BR (1) BR112022013160A2 (https=)
CA (1) CA3166254A1 (https=)
MX (1) MX2022007768A (https=)
TW (1) TW202140415A (https=)
UY (1) UY39007A (https=)
WO (1) WO2021138443A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119202724B (zh) * 2024-09-25 2025-05-30 宁夏医科大学总医院 一种脓毒症心肌病诊断模型的构建方法及诊断系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US9468611B2 (en) * 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
EP2906202A4 (en) * 2012-10-15 2016-04-27 Isa Odidi ORAL DRUG RELIEF FORMULATIONS
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system
CA3064846A1 (en) * 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
EP3917619A4 (en) * 2019-01-30 2022-10-26 University of Padova Structurally modified opioids for prevention and treatment of diseases and conditions

Also Published As

Publication number Publication date
JP2023509484A (ja) 2023-03-08
US20230017786A1 (en) 2023-01-19
WO2021138443A1 (en) 2021-07-08
EP4085044A1 (en) 2022-11-09
MX2022007768A (es) 2022-09-27
BR112022013160A2 (pt) 2022-11-08
UY39007A (es) 2021-07-30
KR20220164470A (ko) 2022-12-13
EP4085044A4 (en) 2024-06-12
CN115397804A (zh) 2022-11-25
CA3166254A1 (en) 2021-07-08
JP2026062924A (ja) 2026-04-10
TW202140415A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
Tian et al. The molecular pathophysiology of depression and the new therapeutics
Ferguson et al. Current and possible future therapeutic options for Huntington’s disease
Grieco et al. Psychedelics and neural plasticity: therapeutic implications
JP7679304B2 (ja) 非サイケデリック／精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法
Samuels et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor
Hayashi et al. An update on the development of drugs for neuropsychiatric disorders: focusing on the σ1 receptor ligand
Iversen Neurotransmitter transporters and their impact on the development of psychopharmacology
JP6245983B2 (ja) パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
Zorumski et al. Treatment-resistant major depression: rationale for NMDA receptors as targets and nitrous oxide as therapy
Das Repurposing of drugs–the ketamine story
Strong et al. NMDA receptor modulators: an updated patent review (2013–2014)
Jamesa et al. The insomnia-addiction positive feedback loop: role of the orexin system
JP7114604B2 (ja) 脆弱ｘ症候群の治療のためのプリドピジンの使用
JP2026062924A (ja) 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
Jones Potential of glial cell modulators in the management of substance use disorders
Scala et al. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
Uyar et al. New and emerging pharmacologic treatments for MDD
Henderson et al. Defining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors
Pierucci et al. Role of central serotonin receptors in nicotine addiction
EP2027856A1 (en) Method of treating or preventing central nervous system disorders with compounds having selectivity benzodiazepine receptor
US20220112153A1 (en) Structurally modified opioids for prevention and treatment of diseases and conditions
Xiao et al. SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile
Ivanov et al. Neurorobiology and evidence-based biological treatments for substance abuse disorders
US20230192715A1 (en) Morphinan isomers and their structural modifications as nmdar antagonists and neuroplastogens
Hu et al. Efficacy of SAL0114, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder